Janney Montgomery Scott
SMMT icon

Janney Montgomery Scott’s Summit Therapeutics SMMT Stock Holding History

Janney Montgomery Scott’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,610
Closed -$340K – 2818
2025
Q1 		$340K Buy
17,610
+1,894
+12% +$38K ﹤0.01% 2232
2024
Q4 		$280K Buy
15,716
+4,443
+39% +$86.1K ﹤0.01% 2352
2024
Q3 		$247K Buy
+11,273
New +$158K ﹤0.01% 2407

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Janney Montgomery Scott's SMMT Position: Q2 2025 in Review

Janney Montgomery Scott sold out of Summit Therapeutics (SMMT) in Q2 2025, closing a stake of 17,610 shares — an estimated $340K sold.

Janney Montgomery Scott first reported a position in SMMT in Q3 2024 and held it in 3 quarters. The position peaked at $340K in Q1 2025. 238 funds tracked by Wall St. Rank hold SMMT as of Q2 2025.

  • Janney Montgomery Scott reported no remaining Summit Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Janney Montgomery Scott sold 17,610 Summit Therapeutics shares in Q2 2025, an estimated $340K.
  • Janney Montgomery Scott first reported a position in Summit Therapeutics in Q3 2024 and held it in 3 quarters.
  • Janney Montgomery Scott's Summit Therapeutics position peaked at $340K in Q1 2025.
  • 238 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2025.

Based on Janney Montgomery Scott's 13F filing for Q2 2025, filed 17 Jul 2025.